Question

A new antibiotic was just approved by the FDA. It is named Aliomycin, and acts much like Oligomycin. With this information and using what we have learned in Unit One, what can you predict about Aliomycin? (What is the relationship with ATP? What about oxygen?)

AND

Do different levels of hemoglobin subtypes impact the symptoms of hemoglobinopathies and thalassemias?

Answer 1

Oligomycins are macrolides created by Streptomyces that can be poisonous to other organisms.

So like Oligomycin A, Aliomycin inhibits ATP synthase by blocking its proton channel (Fo subunit), which is necessary for oxidative phosphorylation of ADP to ATP (energy production). The inhibition of ATP synthesis by oligomycin A/Aliomycin will significantly reduce electron flow through the electron transport chain; however, electron flow is not stopped completely due to a process known as proton leak or mitochondrial uncoupling.

The hemoglobinopathies encompass all genetic diseases of hemoglobin. They fall into two main groups: thalassemia syndromes and structural hemoglobin variants (abnormal hemoglobins). α- and β-thalassemia are the main types of thalassemia; the main structural hemoglobin variants are HbS, HbE and HbC.

Hemoglobin H increases the affinity for oxygen.The levels can be normal to increased in beta thalassemia. Hemoglobin F frequently increases in individuals with sickle cell anemia and sickle cell-beta thalassemia. Individuals with sickle cell and increase of Hb F have a milder case of the disease.